Lung Cancer

S1827

MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

---

A081801

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

---

S1914

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

---

A151804

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

---

URCC 18007

Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue

---

LUNGMAP

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

---

EA5162 (JIT – If a possible patient is identified, notify CRA asap as it will take time to open trial through NCORP)

Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR

---

ECOG E4512 (NCT02201992) **SUSPENDED** – Must have Consented to ALCHEMIST A151216 Trial

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

---

A151216 (NCT02194738) ALCHEMIST

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

---